Skip to main content

Advertisement

Table 3 Arithmetic mean flea counts (percent efficacy) relative to placebo for dogs treated orally with Simparica Trio™ at 3, 4, 8 or 12 h after treatment (Day 0) and weekly re-infestations with Ctenocephalides felis (Study 4)

From: Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs

Count timeTreatment groupDay after treatment
0714212835
3 hPlacebo77.195.089.093.890.498.8
Simparica Trio™77.8
(0)
61.6b
(35.1)
50.1b
(43.7)
88.3
(5.9)
92.8
(0)
93.0
(5.8)
4 hPlacebo72.494.189.593.195.997.4
Simparica Trio™42.8a
(40.9)
43.6b
(53.7)
31.3b
(65.1)
72.1b
(22.6)
85.9
(10.4)
95.9
(1.5)
8 hPlacebo84.088.989.187.894.094.1
Simparica Trio™0b
(100)
0.4b
(99.6)
6.9b
(92.3)
3.6b
(95.9)
26.6b
(71.7)
70.4b
(25.2)
12 hPlacebo85.093.186.692.096.095.3
Simparica Trio™0b
(100)
0b
(100)
0b
(100)
0b
(100)
2.1b
(97.8)
13.8b
(85.6)
  1. aMean live flea counts significantly lower than placebo; t(53) = 4.16, P = 0.0001
  2. bMean live flea counts significantly lower than placebo; 10.09 ≤ tdf ≤ 41.72, 7 ≤ df ≤ 56, P ≤ 0.0138